NURX
Winter 2016AcquiredMedicine or testing kit, prescribed online and delivered to your door.
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Medicine or testing kit, prescribed online and delivered to your door.
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Nurx built an online route to contraception and sexual-health care: intake, licensed-clinician review, pharmacy fulfillment and follow-up. Founded by Hans Gangeskar and Dr. Edvard Engesaeth in 2015, it joined YC W16 and expanded into other recurring care needs.[1][3]
Thirty Madison acquired Nurx on March 14, 2022, for $110 million in stock, according to a later acquisition-history filing submitted to Oregon regulators. Nurx continues as a patient-facing brand. Its trajectory shows both the usefulness of a focused access service and the clinical and pharmacy work required behind it.[4][5]
Image 1 / 1
Gangeskar and Engesaeth chose recurring reproductive care before attempting a general clinic. Their founding aim was to remove barriers to essential care.[3]
The founders said, “we had to work with insurance,” and meet patients' expectation of a zero medication copay. The product therefore had to connect benefits and fulfillment to the online consultation. A convenient questionnaire alone would not solve the price barrier. Their advice also included “Invest in people management and leadership skills” across the organization early.[2]
The founding date and accelerator date are separate. YC lists 2015 as the founding year and Winter 2016 as the batch. The merger announcement describes launching through YC in 2016. A 2022 Thirty Madison founder account instead dated the founding to 2016.[1][3][21]
For birth control, patients submit health history and preferences. A clinician licensed in their state reviews the request and prescribes only when clinically appropriate. Nurx then coordinates delivery, refills and messaging. Current service materials describe three-month shipments and annual prescription-renewal consultations; availability and coverage vary.[5]
The early PrEP pathway added another dependency: required laboratory work before treatment. Its at-home kit moved testing into the same service as consultation and fulfillment. This illustrates the product's operating design, rather than a claim that every patient can receive care remotely.[2]
Nurx's 2019 brand announcement used patient and provider stories and showed what medication and testing materials looked like before arrival. The stated goal was to make an unfamiliar online service easier to understand. That was a deliberate distribution choice around sensitive care, rather than simply a new logo.[8]
The same year exposed an operating weakness. In its public response to press scrutiny, Nurx acknowledged that undelivered sealed medication packages had temporarily been returned to its former corporate office instead of the originating pharmacy. The company said it had ended the practice and had no reason to believe patient safety was affected. Those are company statements, not an independent safety finding.[7]
Nurx also said clinical leadership retained final authority over prescribing protocols. Access and convenience did not remove the need for pharmacy controls or a separate clinical decision. Neither the public response nor the later merger establishes that these issues caused the transaction.[7]
Agile's January 2023 presentation described shared marketing for Twirla and said Nurx providers had prescribed contraception to over one million patients. Its expected channel impact was forward-looking. The relationship demonstrates a manufacturer distribution partnership, not measured treatment outcomes or prescribing independence.[9]
The Pill Club asset purchase later added a different continuity task: moving willing patients to a surviving service. Thirty Madison's release described access to Nurx, while Cooley documented the bankruptcy-sale process. Acquiring patient records did not by itself complete a patient's clinical review or guarantee an uninterrupted refill.[10][11]
Nurx initially served people seeking discreet, recurring reproductive and sexual-health care. Its delivery and asynchronous communication addressed scheduling and pharmacy friction. It subsequently broadened into dermatology, migraine and mental-health services; the current site also advertises menopause and weight-management offerings.[3][5]
Different service lines require different prerequisites, coverage and follow-up. A nationwide brand is not evidence that every condition or patient is eligible in every state.
Twentyeight Health offers contraception, renewals, clinician messaging and delivery or pharmacy pickup, with commercial insurance and Medicaid options. Pandia Health combines hormonal-care consultations, medication coverage and refill coordination. These are current workflow overlaps; their eligibility and fees require their own checks.
The consolidation record also needs precise identities. SimpleHealth's April 2023 transition notice names Twentyeight Health as its successor for eligible patients and records custodian. Separately, Thirty Madison acquired selected Pill Club assets for Nurx. These were distinct transactions, not evidence that Nurx acquired every departing competitor.[20][11]
A new navigation tool must show a specific cross-provider task that existing clinics, pharmacies and patient portals leave incomplete. Nurx's volume does not establish institutional willingness to buy that tool.
Nurx charges separately for consultation, medication and certain support services. Its current fee page lists a $28 annual birth-control consultation, which it does not submit to insurance. Some cash-pay medication starts at $15 monthly; insured medication costs depend on the plan and prescription. A $3 support fee applies in each month when qualifying orders are processed.[6]
These distinctions matter when interpreting a zero-copay advertisement. Medication coverage does not mean the whole service is free. Public evidence here does not establish Nurx's standalone margins, customer-acquisition costs or profitability.
| Measure | Amount | What it describes |
|---|---|---|
| Nurx financing reported in 2022 | $110 million | Prior capital raised, reported by the company. |
| Nurx acquisition consideration | $110 million in stock | March 2022 closing, disclosed in a later regulatory submission. |
| Thirty Madison parent transaction | Just above $500 million, all stock | September 2025 announcement covering the broader company. |
Identical financing and acquisition amounts do not establish an investor return. The later parent-company transaction covers more than Nurx, so it is not a new Nurx valuation.[3][4][14]
Agile's contraception-patient count measures cumulative prescribing reach. Current Nurx marketing reports more than 16 million prescriptions and over 92% ordering again. The page does not supply the reporting window or cohort definition needed to interpret those as an annual retention measure. Neither number establishes clinical effectiveness.[9][5]
At the 2022 merger, deal counsel repeated a combined reach of 750,000 patients and an expected $300 million in first-year revenue. These were combined-company statements and a forecast, not Nurx's standalone financial results.[17]
The useful traction signals are specific: a recurring-care service, a manufacturer partnership, transferred patient relationships and continuing product availability. They support operating relevance while leaving unit economics and clinical outcomes unresolved.
Nurx connected intake, clinical review, coverage and medication delivery. A simpler patient experience depended on coordinating those tasks. The 2019 pharmacy account shows that controlling the journey creates responsibilities beyond software.[5][7]
Thirty Madison's founder said the 2022 combination would unify technology and strengthen relationships with payers, employers and other institutions. This supports management's intended mechanism: more conditions and patient relationships on shared operations. Public sources do not quantify the resulting savings or establish that Nurx could not continue independently.[21]
The 2025 Remedy announcement described combining brands, acquisition capabilities and pharmacy infrastructure. Oregon reviewed the proposed Better Life Health transaction, approved it on October 22 and described Thirty Madison becoming a wholly owned subsidiary. Approval was permission to proceed, not the closing event. Current employer material now says Thirty Madison is part of Remedy; the exact closing date was not established in the observed sources.[14][15][16]
Current terms cover the non-clinical platform and selected Nurx service lines supported by KMG medical groups. The clinical privacy notice identifies Propel Medical and affiliates for other Nurx lines. The division must be checked for the service being used; a consumer brand does not identify one universal clinician organization.[12][13]
Nurx's acquired brand continues. Its history offers a concrete lesson about coordinating access while protecting clinical authority and pharmacy operations. Ownership changes, prescription counts and repeat-order claims do not establish care quality or the financial success of each stakeholder.